XML 19 R33.htm IDEA: XBRL DOCUMENT
v3.19.3

Financing (Tables) | 9 Months Ended
--- | ---
Sep. 27, 2019
Debt Disclosure [Abstract] |
Components Of Debt | The following summarizes the key terms of the offering (€ in millions):
| Aggregate Principal Amount |  | Stated Annual Interest Rate |  | Issue Price (as % of Principal Amount) |  | Maturity Date |  | Interest Payment Dates (in arrears)
2026 Biopharma Euronotes | € | 1,250.0 |  |  | 0.200 | % |  | 99.833 | % |  | March 18, 2026 |  | March 18
2028 Biopharma Euronotes | € | 1,250.0 |  |  | 0.450 | % |  | 99.751 | % |  | March 18, 2028 |  | March 18
2031 Biopharma Euronotes | € | 1,750.0 |  |  | 0.750 | % |  | 99.920 | % |  | September 18, 2031 |  | September 18
2039 Biopharma Euronotes | € | 1,250.0 |  |  | 1.350 | % |  | 99.461 | % |  | September 18, 2039 |  | September 18
2049 Biopharma Euronotes | € | 750.0 |  |  | 1.800 | % |  | 99.564 | % |  | September 18, 2049 |  | September 18
The components of the Company’s debt were as follows ($ in millions):
| September 27, 2019 |  | December 31, 2018
U.S. dollar-denominated commercial paper | $ | — |  |  | $ | 72.8 |
Euro-denominated commercial paper (€2.7 billion and €2.1 billion, respectively) | 2,933.2 |  |  | 2,377.5 |
1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”) | — |  |  | 687.0 |
2.4% senior unsecured notes due 2020 | 499.2 |  |  | 498.5 |
5.0% senior unsecured notes due 2020 (the “2020 Assumed Pall Notes”) | 382.8 |  |  | 386.7 |
Zero-coupon LYONs due 2021 | 34.6 |  |  | 56.2 |
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”) | 277.6 |  |  | 273.2 |
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”) | 872.6 |  |  | 913.2 |
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”) | 272.9 |  |  | 285.7 |
Envista senior unsecured term loan facility due 2022 (the “Envista Term Loan Facility”) | 648.6 |  |  | — |
Envista senior unsecured term loan facility due 2022 (€600.0 million aggregate principal amount) (the “Envista Euro Term Loan Facility”) | 655.6 |  |  | — |
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”) | 546.0 |  |  | 550.7 |
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”) | 871.7 |  |  | 912.6 |
3.35% senior unsecured notes due 2025 | 497.1 |  |  | 496.8 |
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”) | 1,357.5 |  |  | — |
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”) | 284.4 |  |  | 279.9 |
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”) | 651.5 |  |  | 682.0 |
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”) | 1,355.6 |  |  | — |
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”) | 216.0 |  |  | 218.1 |
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”) | 1,900.7 |  |  | — |
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”) | 491.1 |  |  | 483.4 |
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”) | 1,349.2 |  |  | — |
4.375% senior unsecured notes due 2045 | 499.4 |  |  | 499.3 |
1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the “2049 Biopharma Euronotes”) | 810.3 |  |  | — |
Other | 197.2 |  |  | 66.7 |
Total debt | 17,604.8 |  |  | 9,740.3 |
Less: currently payable | 1,068.6 |  |  | 51.8 |
Long-term debt | $ | 16,536.2 |  |  | $ | 9,688.5 |

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(e),(f)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 + Details
Name: | us-gaap_ScheduleOfDebtInstrumentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration